The Latest Breaking News from Food and Drug Administration

A panel of the Food and Drug Administration’s expert advisers on Wednesday voted 6 to 4 against approving Amylyx Pharmaceuticals’ treatment for ALS. The FDA now has until June 29 to decide whether to follow the panel’s advice or let the closely watched drug on to the market.

The stock market gained as consumer confidence rose, peace talks resumed between Russia and Ukraine and vaccine stocks popped.

The Food and Drug Administration’s decision opens a fourth dose of the Pfizer or Moderna vaccines to those people at least four months after their previous booster.

Here's a roundup of top developments in the biotech space over the last 24 hours:

The Food and Drug Administration cast doubt on Amylyx Pharmaceuticals' ALS treatment Monday, leading shares to plummet.

Staar Surgical won Food and Drug Administration clearance for its implantable nearsightedness lens on Monday, leading STAA stock to soar.

IPO stock Amylyx Pharmaceuticals surged Friday ahead of an important Food and Drug Administration meeting to discuss its ALS treatment.

The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher.

The Food and Drug Administration meets next week to review a closely watched drug for ALS, or Lou Gehrig’s disease, following months of lobbying by patient groups and congressional lawmakers

Washington (AFP) - US biotech firm Moderna on Wednesday said it was pursuing regulatory approval for its Covid vaccine in children under six years old after the two-shot regimen was found to be safe and produced a strong immune response.

The psychedelics space was shaken up on the news that MindCure Health (OTC:MCURF) was shutting down operations. After a review process, the company’s board decided that MindCure’s business plan required more capital that it could gather under current market conditions, thus shutting down operations was considered the best move to preserve…